After a two-month battle, OSI Pharmaceuticals said on Sunday that it had agreed to sell itself to Astellas Pharma of Japan for US$4 billion in cash, after its suitor raised its takeover offer.
Under the terms of the deal, OSI shareholders will receive US$57.50 a share, a 55 percent premium to OSI’s share price on Feb. 26, the last trading day before Astellas made its first takeover bid public in March.
The new price is 10.5 percent higher than Astellas’ first proposal of US$52 a share.
The sale ends a standoff over OSI, a biotechnology company whose main product is Tarceva, a drug used to treat several kinds of cancer in conjunction with chemotherapy.
Astellas initially unveiled a US$3.5 billion unsolicited offer in March, which OSI rejected soon after.
After Astellas began a tender offer for OSI’s shares and proposed a rival slate of directors, the US drug maker agreed to open its books to its unsolicited suitor.
Analysts have said that they expected Astellas to prevail, especially given an apparent paucity of rival bidders. But they expected that Astellas would need to raise its bid.
Shares in OSI closed on Friday at US$59.80, up nearly 4.5 percent, as investors expected Astellas to raise its offer for the company. OSI’s stock has risen 61.5 percent since Astellas made its first takeover proposal.
Colin Goddard, OSI’s chief executive, said in a statement: “We believe today’s announcement recognizes the significant value we have built for our stockholders while providing the merged companies the opportunity to forge a stronger collective path forward in a shared mission to provide innovative new medicines to patients around the world.”
Founded in 1983 and based in Melville, New York, OSI’s main product is Tarceva, primarily used to treat lung cancer. The drug generated US$1.2 billion in sales last year. OSI has sought to expand Tarceva’s use in cancer treatment.
The company reported US$75.9 million in net income last year, on US$428.1 million in revenue. It has 524 employees.
Astellas, based in Tokyo and one of Japan’s biggest drug makers, has made it clear that a priority was expanding its oncology drug pipeline.
The deal is a successful effort by Astellas to buy a US biotech company, after losing a battle over CV Therapeutics last year to Gilead Sciences.
“The merger with OSI provides Astellas with a top tier oncology platform in the US and an expanded product portfolio and pipelines,” Astellas chief executive Masafumi Nogimori said in a statement.
PROVOCATIVE: Chinese Deputy Ambassador to the UN Sun Lei accused Japan of sending military vessels to deliberately provoke tensions in the Taiwan Strait China denounced remarks by Japan and the EU about the South China Sea at a UN Security Council meeting on Monday, and accused Tokyo of provocative behavior in the Taiwan Strait and planning military expansion. Ayano Kunimitsu, a Japanese vice foreign minister, told the Council meeting on maritime security that Tokyo was seriously concerned about the situation in the East China and South China seas, and reiterated Japan’s opposition to any attempt to change the “status quo” by force, and obstruction of freedom of navigation and overflight. Stavros Lambrinidis, head of the EU delegation to the UN, also highlighted South China Sea
The final batch of 28 M1A2T Abrams tanks purchased from the US arrived at Taipei Port last night and were transported to the Armor Training Command in Hsinchu County’s Hukou Township (湖口), completing the military’s multi-year procurement of 108 of the tanks. Starting at 12:10am today, reporters observed more than a dozen civilian flatbed trailers departing from Taipei Port, each carrying an M1A2T tank covered with black waterproof tarps. Escorted by military vehicles, the convoy traveled via the West Coast Expressway to the Armor Training Command, with police implementing traffic control. The army operates about 1,000 tanks, including CM-11 Brave Tiger
China on Wednesday teased in a video an aircraft carrier that could be its fourth, and the first using nuclear power, while making an allusion to Taiwan and vowing to further build up its islands, as it looks to boost maritime power, secure resources and bolster territorial claims. The video, issued on the eve of the 77th founding anniversary of the Chinese People’s Liberation Army Navy, featured fictional officers with names that are homophones of three commissioned aircraft carriers, the Liaoning (遼寧), Shandong (山東) and Fujian (福建). Titled Into the Deep, it showed a 19-year-old named “Hejian” (何劍) joining the group, sparking
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s largest contract chipmaker, said it expects its 2-nanometer (2nm) chip capacity to grow at a compound annual rate of 70 percent from this year to 2028. The projection comes as five fabs begin volume production of 2-nanometer chips this year — two in Hsinchu and three in Kaohsiung — TSMC senior vice president and deputy cochief operating officer Cliff Hou (侯永清) said at the company’s annual technology symposium in Silicon Valley, California, last week. Output in the first year of 2-nanometer production, which began in the fourth quarter of last year, is expected to
RSS